Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-266
Closed -$87.1K 249
2025
Q4
$87.1K Buy
266
+2
+0.8% +$634 ﹤0.01% 225
2025
Q3
$74.6K Buy
264
+2
+0.8% +$580 ﹤0.01% 237
2025
Q2
$73.2K Buy
262
+2
+0.8% +$567 ﹤0.01% 229
2025
Q1
$81K Buy
260
+2
+0.8% +$591 ﹤0.01% 223
2024
Q4
$67.2K Sell
258
-2,205
-90% -$654K ﹤0.01% 235
2024
Q3
$794K Buy
2,463
+2
+0.1% +$654 0.03% 147
2024
Q2
$769K Sell
2,461
-58
-2% -$17K 0.03% 150
2024
Q1
$716K Sell
2,519
-183
-7% -$53.5K 0.03% 160
2023
Q4
$778K Buy
+2,702
New +$736K 0.03% 158
2015
Q2
Sell
-1,367
Closed -$222K 321
2015
Q1
$222K Buy
+1,367
New +$215K 0.01% 323
2014
Q4
Sell
-1,464
Closed -$206K 339
2014
Q3
$206K Sell
1,464
-818
-36% -$107K 0.01% 329
2014
Q2
$270K Sell
2,282
-40
-2% -$4.63K 0.02% 323
2014
Q1
$286K Sell
2,322
-410
-15% -$49.7K 0.02% 322
2013
Q4
$312K Buy
2,732
+287
+12% +$32.6K 0.02% 306
2013
Q3
$274K Sell
2,445
-303
-11% -$32.9K 0.02% 316
2013
Q2
$271K Buy
+2,748
New +$285K 0.02% 304

Other funds holding AMGN

Emerald Advisers's AMGN Position: Q1 2026 in Review

Emerald Advisers sold out of Amgen (AMGN) in Q1 2026, closing a stake of 266 shares — an estimated $87.1K sold.

Emerald Advisers first reported a position in AMGN in Q2 2013 and held it in 16 quarters. The position peaked at $794K in Q3 2024. 3,142 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Emerald Advisers reported no remaining Amgen position as of Q1 2026 after selling out during the quarter.
  • Emerald Advisers sold 266 Amgen shares in Q1 2026, an estimated $87.1K.
  • Emerald Advisers first reported a position in Amgen in Q2 2013 and held it in 16 quarters.
  • Emerald Advisers's Amgen position peaked at $794K in Q3 2024.
  • 3,142 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Emerald Advisers's 13F filing for Q1 2026, filed 4 May 2026.